Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. AbbVie (United States)美国3
2. Pfizer (United States)美国3
3. Medical University of South Carolina美国2
4. United States Food and Drug Administration美国2
5. Bristol-Myers Squibb (United States)美国2
6. Georgetown University美国2
7. Daiichi Sankyo (United Kingdom)英国1
8. Indiana University School of Medicine1

按月发文

逐年被引

最新文献

1. 1
   IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical TrialsDrug Safety20250
2. 2
   Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health AdministrationDrug Safety202214
3. 3
   Safety of treating acute liver injury and failureExpert Opinion on Drug Safety202117
4. 4
   Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical TrialsDrug Safety202129
5. 5
   Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisDrug Safety202041
6. 6
   Drug-induced liver injury: a safety reviewExpert Opinion on Drug Safety201842
7. 7
   Hepatotoxicity induced by coxibs: how concerned should we be?Expert Opinion on Drug Safety201637
8. 8
   Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future DirectionsDrug Safety201642

高被引文献

1. 1
   Drug-induced liver injury: a safety reviewExpert Opinion on Drug Safety201842
2. 2
   Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future DirectionsDrug Safety201642
3. 3
   Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisDrug Safety202041
4. 4
   Hepatotoxicity induced by coxibs: how concerned should we be?Expert Opinion on Drug Safety201637
5. 5
   Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical TrialsDrug Safety202129
6. 6
   Safety of treating acute liver injury and failureExpert Opinion on Drug Safety202117
7. 7
   Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health AdministrationDrug Safety202214

主要发表期刊